Jazz Pharmaceuticals plc
JAZZ
$244.96
-$0.89-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.60B | 4.44B | 4.27B | 4.16B | 4.09B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.60B | 4.44B | 4.27B | 4.16B | 4.09B |
| Cost of Revenue | 454.80M | 454.70M | 432.80M | 410.80M | 393.53M |
| Gross Profit | 4.15B | 3.98B | 3.83B | 3.75B | 3.69B |
| SG&A Expenses | 1.54B | 1.51B | 1.67B | 1.65B | 1.60B |
| Depreciation & Amortization | 680.41M | 672.51M | 654.61M | 643.77M | 632.86M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.45B | 3.39B | 3.50B | 3.48B | 3.40B |
| Operating Income | 1.15B | 1.05B | 768.65M | 675.57M | 684.27M |
| Income Before Tax | 727.50M | -219.10M | -628.60M | -703.81M | -512.28M |
| Income Tax Expenses | -213.26M | -248.56M | -272.46M | -335.34M | -107.45M |
| Earnings from Continuing Operations | 940.76 | 29.46 | -356.14 | -368.47 | -404.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 940.76M | 29.46M | -356.14M | -368.47M | -404.83M |
| EBIT | 1.15B | 1.05B | 768.65M | 675.57M | 684.27M |
| EBITDA | 1.87B | 1.76B | 1.46B | 1.36B | 1.36B |
| EPS Basic | 15.26 | 0.47 | -5.78 | -5.96 | -6.60 |
| Normalized Basic EPS | 11.18 | 10.07 | 5.85 | 4.79 | 4.74 |
| EPS Diluted | 14.50 | -0.02 | -5.97 | -6.07 | -6.73 |
| Normalized Diluted EPS | 10.58 | 9.72 | 5.71 | 4.73 | 4.66 |
| Average Basic Shares Outstanding | 246.85M | 244.85M | 243.95M | 243.43M | 244.15M |
| Average Diluted Shares Outstanding | 260.54M | 252.34M | 247.24M | 245.31M | 246.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |